Journal of Breast Cancer

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data

  • Yu, Xiaokang (School of Biology and Biological Engineering, South China University of Technology) ;
  • Liang, Jinsheng (School of Biology and Biological Engineering, South China University of Technology) ;
  • Xu, Jiarui (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) ;
  • Li, Xingsong (School of Biology and Biological Engineering, South China University of Technology) ;
  • Xing, Shan (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Li, Huilan (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Liu, Wanli (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Liu, Dongdong (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) ;
  • Xu, Jianhua (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) ;
  • Huang, Lizhen (School of Biology and Biological Engineering, South China University of Technology) ;
  • Du, Hongli (School of Biology and Biological Engineering, South China University of Technology)
  • Received : 2018.08.06
  • Accepted : 2018.11.09
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Breast cancer is the most commonly occurring cancer among women worldwide, and therefore, improved approaches for its early detection are urgently needed. As microRNAs (miRNAs) are increasingly recognized as critical regulators in tumorigenesis and possess excellent stability in plasma, this study focused on using miRNAs to develop a method for identifying noninvasive biomarkers. Methods: To discover critical candidates, differential expression analysis was performed on tissue-originated miRNA profiles of 409 early breast cancer patients and 87 healthy controls from The Cancer Genome Atlas database. We selected candidates from the differentially expressed miRNAs and then evaluated every possible molecular signature formed by the candidates. The best signature was validated in independent serum samples from 113 early breast cancer patients and 47 healthy controls using reverse transcription quantitative real-time polymerase chain reaction. Results: The miRNA candidates in our method were revealed to be associated with breast cancer according to previous studies and showed potential as useful biomarkers. When validated in independent serum samples, the area under curve of the final miRNA signature (miR-21-3p, miR-21-5p, and miR-99a-5p) was 0.895. Diagnostic sensitivity and specificity were 97.9% and 73.5%, respectively. Conclusion: The present study established a novel and effective method to identify biomarkers for early breast cancer. And the method, is also suitable for other cancer types. Furthermore, a combination of three miRNAs was identified as a prospective biomarker for breast cancer early detection.

Keywords

Acknowledgement

Supported by : Central Universities

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Oncol Pract 2007;3:336-9. https://doi.org/10.1200/JOP.0768504
  3. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804-15. https://doi.org/10.1016/S1470-2045(15)00048-0
  4. Du M, Shi D, Yuan L, Li P, Chu H, Qin C, et al. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep 2015;5:10437. https://doi.org/10.1038/srep10437
  5. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8. https://doi.org/10.1073/pnas.0804549105
  6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006. https://doi.org/10.1038/cr.2008.282
  7. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008;3:e3148. https://doi.org/10.1371/journal.pone.0003148
  8. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010;38:7248-59. https://doi.org/10.1093/nar/gkq601
  9. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515. https://doi.org/10.1371/journal.pone.0013515
  10. Kayala MA, Baldi P. Cyber-T web server: differential analysis of highthroughput data. Nucleic Acids Res 2012;40:W553-9. https://doi.org/10.1093/nar/gks420
  11. Freres P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, et al. Circulating microRNA-based screening tool for breast cancer. Oncotarget 2016;7:5416-28.
  12. Allaya N, Khabir A, Sallemi-Boudawara T, Sellami N, Daoud J, Ghorbel A, et al. Over-expression of miR-10b in NPC patients: correlation with LMP1 and Twist1. Tumour Biol 2015;36:3807-14. https://doi.org/10.1007/s13277-014-3022-6
  13. Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer 2015;14:36. https://doi.org/10.1186/s12943-015-0301-9
  14. Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, et al. High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep 2016;6:24502. https://doi.org/10.1038/srep24502
  15. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, et al. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol 2014;35:7733-41. https://doi.org/10.1007/s13277-014-2025-7
  16. Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem 2015;61:1098-106. https://doi.org/10.1373/clinchem.2015.238691
  17. Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014;9:e96228. https://doi.org/10.1371/journal.pone.0096228
  18. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013;34:163-9. https://doi.org/10.1155/2013/259454
  19. Li J, Song ZJ, Wang YY, Yin Y, Liu Y, Nan X. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer. Genet Mol Res 2016;15(3):gmr8338.
  20. Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Onco Targets Ther 2016;9:6247-55. https://doi.org/10.2147/OTT.S103650
  21. Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 2016;37:461-70. https://doi.org/10.1093/carcin/bgw008
  22. Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 2014;35:11137-45. https://doi.org/10.1007/s13277-014-2412-0
  23. Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, et al. Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet 2014;5:149.
  24. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013;139:223-9. https://doi.org/10.1007/s00432-012-1315-y
  25. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014;8:874-83. https://doi.org/10.1016/j.molonc.2014.03.002
  26. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016;107:326-34. https://doi.org/10.1111/cas.12880
  27. Dai X, Fang M, Li S, Yan Y, Zhong Y, Du B. miR-21 is involved in transforming growth factor beta1-induced chemoresistance and invasion by targeting PTEN in breast cancer. Oncol Lett 2017;14:6929-36.
  28. Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, et al. miR-21-3p is a positive regulator of L1CAM in several human carcinomas. Cancer Lett 2014;354:455-66. https://doi.org/10.1016/j.canlet.2014.08.020
  29. Xia M, Li H, Wang JJ, Zeng HJ, Wang SH. MiR-99a suppress proliferation, migration and invasion through regulating insulin-like growth factor 1 receptor in breast cancer. Eur Rev Med Pharmacol Sci 2016;20:1755-63.
  30. Fan T, Mao Y, Sun Q, Liu F, Lin JS, Liu Y, et al. Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection. Cancer Sci 2018;109:2897-906. https://doi.org/10.1111/cas.13725

Cited by

  1. Sensitive Plasmonic Detection of miR-10b in Biological Samples Using Enzyme-Assisted Target Recycling and Developed LSPR Probe vol.11, pp.21, 2019, https://doi.org/10.1021/acsami.9b03005
  2. Clinical Translatability of “Identified” Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update vol.11, pp.7, 2019, https://doi.org/10.3390/cancers11070901
  3. lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer vol.13, pp.None, 2018, https://doi.org/10.2147/ott.s240769
  4. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.586268
  5. Peripheral Blood-Based Biopsy for Breast Cancer Risk Prediction and Early Detection vol.7, pp.None, 2018, https://doi.org/10.3389/fmed.2020.00028
  6. Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer vol.21, pp.19, 2018, https://doi.org/10.3390/ijms21197427
  7. La biopsia líquida en el diagnóstico y monitoreo de pacientes oncológicos: oportunidades y retos en Latinoamérica vol.24, pp.4, 2020, https://doi.org/10.35509/01239015.44
  8. ARMT: An automatic RNA-seq data mining tool based on comprehensive and integrative analysis in cancer research vol.19, pp.None, 2021, https://doi.org/10.1016/j.csbj.2021.08.009
  9. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue vol.22, pp.9, 2021, https://doi.org/10.3390/ijms22094673
  10. MiR-106b-5p: A Master Regulator of Potential Biomarkers for Breast Cancer Aggressiveness and Prognosis vol.22, pp.20, 2018, https://doi.org/10.3390/ijms222011135
  11. Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways vol.16, pp.11, 2021, https://doi.org/10.1371/journal.pone.0260327